Metacrine
2014
FOUNDED
PRIVATE
STATUS
21-30
EMPLOYEES
Series C
LATEST DEAL TYPE
$65M
LATEST DEAL AMOUNT
14
INVESTORS
Description
Develop of therapeutics that materially benefit patients with liver, GI and metabolic diseases. The company's are based on a novel non-bile acid chemical scaffold and a nuclear hormone receptor that has been clinically validated as a key drug target in hepatobiliary diseases such as primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) enabling patients to avail two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Primary Office
- 3985 Sorrento Valley Boulevard
- Suite C
- San Diego, CA 92121
- United States
+1 (858) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Metacrine’s full profile, request a free trial.
Metacrine Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C) | 06-Jun-2018 | $65M | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 2. Early Stage VC (Series B) | 07-Dec-2017 | 0000 | 000.00 | 0000 | Completed | Startup |
| 1. Early Stage VC (Series A) | 02-Nov-2016 | $37.8M | $37.8M | 0000 | Completed | Startup |
Metacrine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 00,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series A | 36,099,978 | $0.000100 | 6% | $1 | $1 | 1x | $1 | 35.6% |
Metacrine Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| ArrowMark Partners | Asset Manager | Minority | 000 0000 | 000000 0 | ||
| Deerfield Management | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Franklin Templeton Investments | Asset Manager | Minority | 000 0000 | 000000 0 | ||
| Invus Group | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| Lilly Asia Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
Metacrine Executive Team (9)
2 Former Executives
You’re viewing 5 of 9 executives. Get the full list »Metacrine Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Amir Nashat Ph.D | Polaris Partners | Board Member | 000 0000 | |
| Carol Gallagher | New Enterprise Associates | Board Member | 000 0000 | |
| Ken Song MD | Metacrine | President, Chief Executive Officer & Board Director | 000 0000 | |
| Kristina Burow | ARCH Venture Partners | Board Member | 000 0000 | |
| Richard Heyman Ph.D | Self | Executive Chairman & Co-Founder | 000 0000 |